Explore more publications!

Sci-Tech Seattle: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Seattle.

Press releases published on October 2, 2025

ポップロ (Poppulo)、従業員コミュニケーションおよびデジタルサイネージ企業として初めて、責任あるAIに関するベンチマークISO認証を取得
Poppulo, 책임 있는 AI를 위한 ISO 인증 벤치마크 획득…직원 커뮤니케이션 및 디지털 사이니지 업계에선 최초
Poppulo กลายเป็นบริษัทสื่อสารและป้ายดิจิทัลสำหรับพนักงานรายแรกที่ได้รับการรับรองมาตรฐาน ISO สำหรับ AI ที่มีความรับผิดชอ…
Poppulo 成为首家获得负责任 AI 基准 ISO 认证的员工通讯与数字标牌企业
Poppulo Menjadi Syarikat Komunikasi Pekerja dan Papan Tanda Digital Pertama yang Meraih Pensijilan ISO Penanda Aras bagi AI Bertanggungjawab
Poppulo É a Primeira Empresa de Comunicações e Sinalização Digital de Funcionários a Obter a Certificação ISO de Referência Como IA Responsável
Poppulo 成為首間獲得負責任 AI 基準 ISO 認證的員工通訊與數碼告示板公司
Datavault AI Converts $13.3 Million in Convertible Debt, Strengthens Balance Sheet
AiSprouts Launches Founder Bootcamp Program to Support the Next Wave of Capital-Efficient Artificial Intelligence Startups
SmartDeFi™ Announces GENIUS Act-Compatible Token Launching Options
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mevolaxy Introduces New mevjrv12 Algorithm, Offering users Record Profits
Matrack Takes Home Two Awards at 2025 NATDA Trailer Show Innovation Showcase
Folks Achieves Prestigious Ranking in Canada's Top Growing Companies 2025
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
Rumble and Perplexity Enter into a Strategic Partnership
Dyne Therapeutics Appoints Brian Posner to its Board of Directors

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions